Please note: Timings are in CET (Central European Time) 

  1. Session 4: Sustainability and the BPR
  2. Updates on the high-level round table discussions and the likely impacts of the Reach/CLP reviews on the biocides sector

    • Recent developments in the REACH/CLP review
    • Links between Reach and biocides regulation
    • New hazard classes
    • Possible implications for active substance approval and product authorisation
    Paul Krajnik Paul Krajnik
    Deputy Director Chemicals and Biocides, Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology, Austria
  3. The EU Chemical Strategy for Sustainability (CSS): What does it mean for biocides?

    • The Green Deal and CSS: compliance of biocides? 
    • Impact assessment and socio-economic analysis (SEA) 
    • A strategy for biocides 
    Marcel Hulsman Marcel Hulsman
    Partner Product Stewardship, Biocides, ERM, the Netherlands
  4. The Blue Angel ecolabel approach to antifouling

    • 100 non-biocidal antifouling systems identified for the German market
    • 14 different mechanisms of action
    • Proofs of concept and banned substances 
    Bernd Daehne Bernd Daehne
    Director of Antifouling Research Station, Dr. Brill + Partner - Institute for Antifouling and Biocorrosion
  5. Q&A

  6. Refreshment break

  7. Session 4: Sustainability and the BPR, continued
  8. Legal perspective: Implications of sustainability regulations for companies in the biocides sector

    • Context and drivers for sustainability  
    • Current successes, difficulties and opportunities 
    Koen Van Maldegem Koen Van Maldegem
    Partner, EU Regulatory, Fieldfisher LLP, Belgium
    Gerard McElwee Gerard McElwee
    Partner, EU Regulatory, Fieldfisher LLP
  9. Biocides and sustainable use

    Camelia Mihai Camelia Mihai
    Team Lead Biocides, Biocides For Europe, Cefic, Belgium
  10. Panel discussion on biocides and sustainable use

  11. Lunch

  12. Chemical Watch demo

    Lauren True Lauren True
    Marketing Manager, Chemical Watch
  13. Session 5: The assessment of endocrine disrupting chemicals under the BPR
  14. Scientific criteria to identify endocrine chemicals

    • What are the new methods and their implementation within regulatory assessment? 
    • How to build the weight of evidence?  
    • Why is mechanistic toxicology required for ED assessment?  
    • Endocrine activity versus adverse outcome?  
    Gregory Lemkine Gregory Lemkine
    CEO, Watchfrog Laboratory
  15. The latest developments and significant legal issues arising on ED assessments

    • Are the BPR’s ED criteria implementable?  
    • Data rights issues 
    • Impact of chemicals strategy for sustainability
      • ED as a new hazard class under the Regulation on the classification, labelling and packaging of substances and mixtures (CLP)
      • One substance, one assessment 
    Darren Abrahams Darren Abrahams
    Partner, Barrister & Avocat, Steptoe International (UK) LLP
    Hannah Widemann Hannah Widemann
    Senior Associate, Chemical and Life Sciences, Steptoe & Johnson LLP
  16. Q&A

  17. Refreshment break

  18. Session 6: Efficacy updates
  19. Efficacy evaluation of disinfectants PT 1 to 5, PT 21 and treated articles PT 10 based on current development and Echa efficacy guidance including biofilm-activity testing

    • Overview of current activity test methods for PT 1 – 5, PT 10 and PT 21
    • Update on latest resistance developments
    • Biofilm activity methods – quo vadis?
    Florian H H Brill Florian H H Brill
    Owner and Managing Director, Dr Brill + Partner GmbH, Institut für Hygiene und Mikrobiologie
  20. Efficacy – beyond the guidance

    • The applicant​
    • The assessor​
    • The efficacy method provider​
    David Ashworth David Ashworth
    Managing Director, Klarus Consulting Ltd, UK
  21. Simulated use test and field trial for PT5 claims and applications

    • PT 5 claim matrix and Echa test requirements 
    • Simulated use test – validation requirements (case study: UBA test) 
    • Robust field trial experimental design (case study: animal drinking water facility) 
    Michele Cavalleri Michele Cavalleri
    Biomed & GLP Facility Manager, Eurofins Biolab
  22. Q&A

  23. End of conference

View previous day

/ next day